Organovo Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
VivoSim Labs, Inc. (VIVS) has transitioned from a clinical-stage biotechnology company to a pharmaceutical and biotechnology services provider focused on 3D human tissue models for drug testing.
VivoSim Labs, Inc. filed an amendment to its annual report to provide detailed information on executive compensation, corporate governance, and related party transactions, including a change in its Chief Financial Officer and auditor, while its auditor noted substantial doubt about the company's ability to continue as a going concern.
VivoSim Labs, Inc. has strategically shifted its business focus to providing 3D human tissue models for drug testing, securing an initial $10 million from Eli Lilly for its former FXR program, while successfully regaining compliance with Nasdaq listing requirements.
10-K/A: Organovo Holdings Files Amended Annual Report, Discloses Executive and Director Compensation Details
Organovo Holdings has filed an amendment to its annual report to include previously omitted information regarding executive compensation, director details, and corporate governance.
Organovo Holdings, a clinical-stage biotech company, released its 10-K filing for the fiscal year ended March 31, 2024, highlighting its focus on advancing FXR314 for inflammatory bowel disease and developing 3D human tissue models for drug discovery.